SLSheng-Qing Lv

Sheng-Qing Lv

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sheng-Qing Lv has a total of 307 co-authors. Here are the top co-authors by number of shared publications:

  • Guo-Hao Huang

    Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, PR China; Department of Neurosurgery, Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing, 400037, PR China

    12 shared publications
  • Yan Xiang

    Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China

    12 shared publications
  • Lin Yang

    Department of Neurosurgery, Xinqiao Hospital, Army Medical University, Chongqing City 400037, PR China

    7 shared publications
  • Jun-Hai Tang

    Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, People's Republic of China

    6 shared publications
  • Lei Du

    Department of Neurosurgery, The 42nd Hospital of the Chinese People's Liberation Army, Leshan City, Sichuan 614100, People's Republic of China

    5 shared publications
  • Shiyong Liu

    Epilepsy Research Center of PLA, Department of Neurosurgery Xinqiao Hospital, Army Medical University Chongqing P.R. China

    5 shared publications

Latest Publications

  • Open Access

    CD44 Predisposes the Epileptogenesis of Cortical Tubers by Regulating CASK and Acts as a Potential Biomarker to Identify Epileptogenic Tuber in Tuberous Sclerosis Complex

    by Zhongke Wang, Kaixuan Huang, Xingye Liu, Yang Li, Shujing Li, Jie Li, Hu Li, Jingze Wang, Zeng He, Limeng Sun, et al.

    Background: Tuberous sclerosis complex (TSC) is characterized by developmental delay and intractable epilepsy, with multiple cortical tubers in the brain. However, the mechanism underlying epileptogenesis within these tubers remains unclear. Methods: RNA sequencing (RNA‐seq) analysis of resected human cortical tubers identified differential CD44 expression as a potential contributor to TSC epilepsy. By analyzing clinical characteristics, resected brain tissues, 18 F‐fludeoxyglucose PET images, cultured cortical neurons, and neocortical seizure animal models, the effect of CD44 on the epileptogenesis of cortical tubers was investigated. Results: Increased CD44 expression was found in human Epi tubers compared with non‐Epi tubers and closely correlated with the clinical characteristics of Epi tubers. CD44 activation increased neocortical seizure susceptibility and aggravated cortical pyramidal neuronal excitatory/inhibitory (E/I) imbalance. CASK was selected as the downstream target of CD44 using RNA‐seq. Anti‐CD44 monoclonal antibodies rescued the E/I imbalance in resected Epi tubers, and CD44 activation rescued the decreased firing frequency and increased action potential threshold induced by CASK inhibition. The CD44–CASK pathway exhibited diagnostic potential for identifying Epi tubers and predicting surgical outcomes via ROC analysis. Conclusion: CD44 activation predisposes cortical tubers to epileptogenesis, and could be a potential biomarker for identifying Epi tubers and predicting surgical outcomes in TSC patients.

  • Integrated multi-omics analyses decipher molecular subtype-associated tumor microenvironment patterns in glioma

    by Guo-Hao Huang, Meng-Li Zhu, Qian Yan, Hong Zhou, Qu-Jing Gai, Yue-Xi Zhu, Shuai Zhang, Zi-Dong Liu, Wei Chen, Jing-Peng Liu, et al.

  • Open Access

    Multi-omics and machine learning approaches uncover metabolic biomarkers for diagnosis of germinoma

    by HuaChun Yin, Yong Chen, LuSheng Li, YuYang Peng, Ying Xiong, JingXin Tao, ShengQing Lv, Hui Yang, Shuai Tan, Bo Li, et al.

  • Open Access

    EDNRB‐dependent endothelin signaling reduces proliferation and promotes proneural‐to‐mesenchymal transition in gliomas

    by Donovan Pineau, Leonor Garcia, Hugo Arnold, Antonija Hanžek, Maialen Arrieta, Laurent R Gauthier, Christine Granotier‐Beckers, François D Boussin, Amaury Herbet, Marie Hautière, et al.

    Diffuse gliomas are primary brain tumors including glioblastomas (GB), astrocytomas, and oligodendrogliomas, the latter two harboring IDH1 mutations and exhibiting slower progression. Gliomas display cellular plasticity, with transitions between astrocyte‐like, oligodendrocyte‐like, progenitor‐like, and mesenchymal‐like states driven by genetic alterations and microenvironmental signals. The proneural‐to‐mesenchymal transition (PMT), associated with increased malignancy, is tightly regulated by the tumor microenvironment, notably through cytokine signaling and non‐tumor cell interactions. Endothelins (ET‐1, ET‐2, ET‐3), vasoactive peptides mainly produced by vascular cells, signal through the G‐protein‐coupled receptors EDNRA and EDNRB and were previously suggested to promote glioma proliferation based on serum‐based models. Here, we revisited endothelin signaling using eleven serum‐free glioma lines and tumor samples. Multi‐omics and electrophysiological analyses identified EDNRB as the predominant receptor, enriched in astrocyte‐like cells, increased by BMPs or growth factor withdrawal, and repressed by interferons, IL‐6 family cytokines, endothelins, and Hippo/YAP signaling. EDNRA was confined to a perivascular tumor subpopulation and induced by Notch signaling selectively in GB. Functionally, endothelins reduced proliferation while promoting migration and PMT via EDNRB‐dependent Ca 2+ signaling, ERK/STAT3 activation, and apamin‐sensitive SK2/SK3 potassium channel activity. Collectively these findings establish endothelin signaling as an important regulator of glioma cell plasticity and behavior.


  • Open Access

    Investigating the Dual Role of Lactate in Temporal Lobe Epilepsy: Energy Substrate Versus HCAR1‐Mediated Inhibitory Signaling

    by Jian-Ping Song, Kai-Feng Shen, Bin Yu, Li Wang, Ya Lei, Lu-Kang Wang, Xiao-Lin Yang, Gang Zhu, Zhi-Feng Wu, Sheng-Qing Lv, et al.

    Temporal lobe epilepsy (TLE) is the most common type of drug‐resistant epilepsy in adults, yet further mechanistic understanding is still needed. Lactate is mass‐produced during seizures and serves as epileptic fuel afterward, while it also acts as an inhibitory molecule by activating its receptor, hydroxycarboxylic acid receptor 1 (HCAR1). This study is aimed at clarifying the balance between lactate′s role in fueling or inhibiting seizures in patients and animal models with TLE. Lactate was measured in the hippocampus with magnetic resonance spectroscopy (MRS). The expression of lactate dehydrogenase (LDH), monocarboxylate transporter 4 (MCT4), and HCAR1 was quantified with immunostaining and immunoblotting. shRNA and pharmacological manipulation were used to modulate the function of MCT4 or HCAR1 in in vitro and in vivo recording. Results showed that lactate was accumulated in the hippocampal lesions of TLE patients, attributing to the increased lactate catalytic activity of astrocytic LDH. The expressional level of MCT4, which mediated the transmembrane lactate transportation in astrocytes, was increased, whereas inhibition of MCT4 decreased the excitatory synaptic transmission and knockdown of astrocytic Mct4 ameliorated seizure activities in TLE mice. HCAR1 was increased in the hippocampal lesions, and activation of lactate‐HCAR1 signaling attenuated seizure activities in TLE mice. Additionally, the alteration in lactate homeostasis was correlated with seizure frequency in TLE patients and could be modulated by ketogenic diet in TLE mice. These data suggest that the inhibitory signaling effect of lactate is outweighed by its fueling role in TLE. Precisely targeting MCT4 or HCAR1 could be effective antiepileptic strategies.

  • Machine learning-based preoperative prediction of IDH mutation status in adult gliomas using clinical features

    by Wei Chen, Peng Ren, Guo-Hao Huang, Jing-Peng Liu, Cheng Yang, Fei Li, Sheng-Qing Lv

    As isocitrate dehydrogenase (IDH) mutation status represents a critical prognostic factor in adult gliomas, there is a demand for a straightforward but effective predictive model to facilitate rapid preoperative diagnosis. A cohort of 418 adult glioma patients from our institution were retrospectively enrolled and randomly partitioned into training (70%) and internal validation (30%) sets. Among 9 machine learning algorithms evaluated, AdaBoost demonstrated superior predictive performance based on receiver operating characteristic (ROC) analysis and was subsequently selected as the optimal model. Through feature importance ranking derived from the model, the top 8 most contributory features were identified and incorporated into the final streamlined prediction model. The model's generalizability was further assessed using an independent external validation cohort comprising 206 adult glioma cases. The AdaBoost model demonstrated robust discriminative performance, achieving an area under the receiver operating characteristic curve (AUC-ROC) of 0.901 in the internal validation cohort and 0.849 in the independent external validation cohort. SHAP (SHapley Additive exPlanations) interpretation revealed age as the most influential predictive feature, contributing significantly to the model's decision-making process. This validated AdaBoost model offers a practical and interpretable solution for preoperative IDH status assessment, demonstrating both diagnostic reliability and biological plausibility through its feature importance profile.

  • Open Access

    Modified Target Delineation and Moderately Hypofractionated Radiotherapy for High-Grade Glioma

    by Liangzhi Zhong, Pu Zhou, Lu Chen, Diangang Chen, Li Wen, Xinwei Diao, Anmei Zhang, Yixing Gao, Guangpeng Chen, Xueqin Li, et al.

    Importance: Optimizing irradiation volumes and evaluating the effect of dose escalation on total and fractionated doses are critical for improving outcomes in high-grade glioma (HGG).Objective: To assess the efficacy of modified target delineation guided by multimodal magnetic resonance imaging and white matter tracts combined with moderately hypofractionated simultaneous boost intensity-modulated radiotherapy (HSIB-IMRT) in patients with newly diagnosed HGG.Design, Setting, and Participants: This single-center, 2-arm, open-label randomized clinical trial enrolled 154 patients aged 18 to 70 years with histologically confirmed, newly diagnosed HGG at a Chinese medical center from January 1, 2018, to August 31, 2022. Follow-up was completed in June 2024.Interventions: Patients were randomized to receive modified target delineation guided by multimodal magnetic resonance imaging and white matter tracts combined with HSIB-IMRT (experimental arm) or standard IMRT per guideline recommendations (standard arm). Both arms received concurrent and adjuvant temozolomide chemotherapy.Main Outcomes and Measures: The primary end point was progression-free survival (PFS). The secondary end point was overall survival (OS).Results: Among 154 enrolled patients (76 in the experimental arm and 78 in the standard arm; 85 [55.2%] male; median [range] age, 51.5 [23.0-70.0] years), the median (range) follow-up duration was 22 (4-76) months, with 96 deaths by June 2024. The median PFS was 15.5 months (95% CI, 11.7-19.3 months) in the experimental arm and 13.5 months (95% CI, 8.7-18.3 months) in the standard arm (P = .89). The median OS was 27.0 months (95% CI, 13.9-40.1 months) in the experimental arm and 21.0 months (95% CI, 18.0-24.0 months) in the standard arm (P = .24). The clinical target volume in the experimental arm (CTV1: median [range], 116.7 [20.2–370.7 cm3]; CTV2: median [range], 174.4 [34.5-463.2 cm3]) was significantly smaller than the clinical target volume in the standard arm (median [range], 225.0 [70.2-542.1 cm3]; P < .001). Recurrence rates within, outside, and multicentric to the target volume were comparable between arms. Grade 3 or 4 adverse events occurred in 4 patients (5.3%) in the experimental arm and 3 (3.8%) in the standard arm (P = .72).Conclusions and Relevance: In this randomized clinical trial, modified target delineation with HSIB-IMRT demonstrated comparable PFS and OS to standard IMRT in patients with newly diagnosed HGG, while significantly reducing the irradiation target volume without increasing the recurrence rates outside the target volume. These results suggest valuable insights for future research aimed at personalized, reduced volume strategies to optimize outcomes and minimize neurotoxicity in HGG.Trial Registration: ChiCTR.org.cn Identifier: ChiCTR1800014396


  • Open Access

    Single-cell analysis of a progressive Rosai–Dorfman disease affecting the cerebral parenchyma: a case report

    by Guo-Hao Huang, Guo-Long Liu, De-Zhi Huang, Xin-Wei Diao, Sheng-Qing Lv

    Neurologic Rosai–Dorfman disease (RDD) is a rare type of non-Langerhans cell histiocytosis that affects the central nervous system. Most neurologic RDDs grow like meningiomas, have clear boundaries, and can be completely resected. However, a few RDDs are invasive and aggressive, and no effective treatment options are available because the molecular mechanisms involved remain unknown. Here, we report a case of deadly and glucocorticoid-resistant neurologic RDD and explore its possible pathogenic mechanisms via single-cell RNA sequencing. First, we identified two distinct but evolutionarily related histiocyte subpopulations (the C1Q+ and SPP1+ histiocytes) that accumulated in the biopsy sample. The expression of genes in the KRAS signaling pathway was upregulated, indicating gain-of-function of KRAS mutations. The C1Q+ and SPP1+ histiocytes were highly differentiated and arrested in the G1 phase, excluding the idea that RDD is a lympho-histio-proliferative disorder. Second, although C1Q+ histiocytes were the primary RDD cell type, SPP1+ histiocytes highly expressed several severe inflammation-related and invasive factors, such as WNT5A, IL-6, and MMP12, suggesting that SPP1+ histiocytes plays a central role in driving the progression of this disease. Third, oligodendrocytes were found to be the prominent cell type that initiates RDD via MIF and may resist glucocorticoid treatment via the MDK and PTN signaling pathways. In summary, in this case, we report a rare presentation of neurologic RDD and provided new insight into the pathogenic mechanisms of progressive neurologic RDD. This study will also offer evidence for developing precision therapies targeting this complex disease.


  • Open Access

    Elevated Fras1-related extracellular matrix 3 in isocitrate dehydrogenase 1-mutant astrocytoma World Health Organization grade 4 predicts favorable prognosis in glioma: A bioinformatic and experimental analysis

    by Zuoxin Zhang, Guohao Huang, Tingting Wang, Yuchun Pei, Guolong Liu, Lin Yang, Yan Xiang, Qiuzi Chen, Shuo Zhou, Xingyu Zhou, et al.

    Background and Aim: World Health Organization (WHO) grade 4 glioma is a malignancy of the central nervous system characterized by refractoriness to treatment and a high mortality rate. Isocitrate dehydrogenase (IDH) mutation is a crucial molecular event for the classification of glioma and associated with prognosis and exploring genetic and molecular differences between IDH mutant and wildtype glioma is crucial. The aim of this study was to investigate the prognostic gene between IDH mutant and wildtype WHO grade 4 glioma and its functional significance. Materials and Methods: The mRNA expression profile data of WHO grade 4 glioma were downloaded from the Gene Expression Omnibus and Chinese Glioma Genome Atlas databases. Bioinformatic analysis was performed to identify the differentially expressed genes between IDH1-mutant and wildtype WHO grade 4 glioma. Survival analysis, functional enrichment analysis, immune cell infiltration evaluation, and in vitro experimental validation were conducted to evaluate the prognostic and functional significance of Fras1-related extracellular matrix 3 (FREM3). This study was approved by the Institutional Ethics Committee of Xinqiao Hospital, Third Military Medical University (approval No. 2021-Y068-01). Results: Elevated expression of FREM3 in IDH1-mutant WHO grade 4 astrocytoma predicted favorable prognosis in glioma. FREM3 was negatively associated with epithelial–mesenchymal transition (EMT), angiogenesis, and hypoxia; notably, low expression of FREM3 was associated with a higher degree of immune cell infiltration. In vitro experiments demonstrated that high FREM3 expression might attenuate the process of EMT and cellular proliferation in glioma. Conclusions: The gene FREM3 plays a major role in IDH1-mutant WHO grade 4 glioma and elevated FREM3 predicts a favorable prognosis of glioma. Further investigation on FREM3 is warranted to elucidate the mechanisms underlying the malignant evolution of glioma.